FindTrial
Sign In

Study of a skincare product to reduce pores and oil and improve skin glow, texture, and even tone

To evaluate in-vivo safety and efficacy of skin care formulation in terms of reduction in pores, blackheads, whiteheads, skin oiliness, and improvement in skin texture, skin brightness, skin even tone and skin barrier function on healthy male and female subjects - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106560
Enrollment
36
Registered
2026-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: CUCUMBER TONER: Product is applied on the whole face one time in a day for the period of 28 days Control Intervention1: Nil: NA

Sponsors

Bio Veda Farmacy Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Indian male & female subjects 2.Healthy subjects 3.Skin is healthy on the studied anatomic unit 4.Having dull oily skin with visible pores.

Exclusion criteria

Exclusion criteria: 1 For female:- Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having a progressive asthma (either under treatment or last fit in the last 2 years) 6 Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis) 7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8 Being epileptic. 9 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 10 Having cutaneous hypersensitivity. 11 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 12 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Reduction in pores, blackheads, whiteheads, skin oiliness, and improvement in skin texture, skin brightness, skin even tone and skin barrier functionTimepoint: Baseline, 30 minutes after application, Day 7,Day 14, Day 28—

Secondary

MeasureTime frame
Improvement in skin smoothness, skin softness, skin clarity, and reduction in acne count and acne PIH spotsTimepoint: Baseline, 30 minutes after application, Day 7,Day 14, Day 28—

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

niharika@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026